Background-Decreased endothelial nitric oxide (NO) synthase (eNOS) activity and NO production are critical contributors to the endothelial dysfunction and vascular complications observed in many diseases, including diabetes mellitus. Extracellular nucleotides activate eNOS and increase NO generation; however, the mechanism of this observation is not fully clarified. Methods and Results-To elucidate the signaling pathway(s) leading to nucleotide-mediated eNOS phosphorylation at Ser-1177, human umbilical vein endothelial cells were treated with several nucleotides, including ATP, UTP, and ADP, in the presence or absence of selective inhibitors. These experiments identified P2Y1, P2Y2, and possibly P2Y4 as the purinergic receptors involved in eNOS phosphorylation and demonstrated that this process was adenosine independent. Nucleotide-induced eNOS phosphorylation and activity were inhibited by BAPTA-AM (an intracellular free calcium chelator), rottlerin (a protein kinase C␦ inhibitor), and protein kinase C␦ siRNA. In contrast, blockade of AMP-activated protein kinase, calcium/calmodulin-dependent kinase II, calcium/calmodulin-dependent kinase kinase, serine/threonine protein kinase B, protein kinase A, extracellular signal-regulated kinase 1/2, and p38 mitogen-activated protein kinase did not affect nucleotide-mediated eNOS phosphorylation. 
N itric oxide (NO) is an important signaling molecule, regulating inflammation, angiogenesis, and thrombosis. 1 However, in certain diseases, including atherosclerosis and diabetes mellitus, endothelial NO synthase (eNOS) expression and activity are strongly attenuated, impairing NO production. 2 NO generated and released from the endothelium promotes vasorelaxation, protects endothelial cells (ECs) from apoptosis, inhibits vascular smooth muscle cell proliferation, blocks platelet activation, and enhances vascular growth. NO synthesis requires the activation of a family of enzymes called NOSs. Three NOS isoforms have been identified: 1 inducible form and 2 constitutive forms, neuronal NOS and eNOS. The expression and function of eNOS are regulated at multiple levels, namely transcriptional, posttranscriptional (mRNA stability), and posttranslational (O-glycosylation, myristoylation, palmitoylation, and phosphorylation). Additional regulation occurs through eNOS dimerization and interaction with regulatory proteins such as calmodulin, caveolin-1, and heat-shock protein 90, as well as eNOS subcellular targeting to caveolae, other cellular membranes, or the cytoplasm. 3, 4 Clinical Perspective p 879 eNOS is activated by various stimuli, including thrombin, bradykinin, vascular endothelial growth factor (VEGF), tumor necrosis factor-␣, histamine, insulin, acetylcholine, endothelin-1, and angiotensin II. Agonist stimulation of the specific receptors activates phospholipase C␥, which is followed by an increase in diacylglycerol and an increase in intracellular free calcium concentration ([Ca 2ϩ ] i ), activating calmodulin. Ca 2ϩ /calmodulin binds to the calmodulin-binding domain in eNOS and allosterically activates eNOS. In addition, calmodulin can activate calcium/calmodulin-dependent kinase (CaMK) II, which further activates eNOS by phosphorylation of Ser-1177. 5 Although the main signal transduction pathway of agonist-stimulated eNOS activation depends on Ca 2ϩ /calmodulin, eNOS activity can be additionally regulated via its phosphorylation by various other kinases, including phosphoinositol 3-kinase (PI3K)/Akt, AMP-activated protein kinase (AMPK), extracellular signal-regulated kinase 1/2 (ERK), p38 mitogen-activated protein kinase (MAPK), protein kinase C (PKC), and protein kinase A (PKA). 6 -12 Classically, eNOS phosphorylation at Ser-1177 is mandatory for its activation, whereas phosphorylation of Thr-495 by PKC␤II has been linked to loss of eNOS activity. 13, 14 Interestingly, extracellular nucleotides also have been implicated in activation of eNOS, leading to NO generation and vasodilation. 15 Nucleotides are released into extracellular fluids by exocytosis from nucleotide-containing granules, by efflux through a membrane transport system in response to cell activation, or as a consequence of cell death. Extracellular nucleotides function as paracrine or autocrine mediators via activation of their respective purinergic P2 receptors. 16 On the basis of molecular structure and function, P2 receptors are classified into 2 main groups: P2X, ligand-gated ion channels, and P2Y, G protein-coupled receptors. 17 Seven P2X receptors subtypes (P2X1 through P2X7) and 8 P2Y receptor subtypes (P2Y1, P2Y2, P2Y4, P2Y6, and P2Y11 through P2Y14) have been characterized to date. Although P2X receptors facilitate the entry of extracellular Ca 2ϩ , activation of P2Y receptors results in Ca 2ϩ release from intracellular stores. 18 P2X receptors are exclusively activated by ATP, whereas P2Y receptors respond to both purine (ATP, ADP) and pyrimidine (UTP, UDP) nucleotides. Specifically, ADP is the preferential ligand of P2Y1 and P2Y12 receptors; ATP is the ligand for P2Y2, P2Y11, and P2Y13 receptors; UTP is the ligand of P2Y2 and P2Y4 receptors; UDP is the ligand of P2Y6; and UDP-glucose is the ligand of P2Y14. 17 Most cells express multiple P2 receptor subtypes. In particular, ECs express P2Y1, P2Y2, P2Y4, P2Y6, and P2Y11 receptors. 19 Activation of the various P2 receptors by nucleotides initiates multiple signaling pathways, including the Akt and focal adhesion kinase/paxillin pathways, as well as the activation of several kinases such as AMPK, ERK, p38, and Jun N-terminal kinase. 20 -22 This leads to cytoskeletal changes and modulation of expression of several genes involved in the regulation of cell proliferation and apoptosis.
The aim of the present study was to elucidate the signaling pathway(s) involved in nucleotide-mediated phosphorylation of eNOS at Ser-1177. Our results unravel a novel nucleotidetriggered pathway that phosphorylates eNOS by increasing [Ca 2ϩ ] i and activating PKC␦. 
Methods

Reagents
Cell Culture
Human umbilical vein ECs (Cambrex, Walkersville, Md) were cultured in an EGM-2 Bullet Kit medium containing human epidermal growth factor, hydrocortisone, human fibroblast growth factor, VEGF, ascorbic acid, gentamicin, amphotericin-B, human insulinlike growth factor, heparin, and 5% (vol/vol) FBS at 37°C in a 5% CO 2 humidified air incubator. Confluent cells at passage 4 or 5 were used in all experiments.
Cell Treatment and Cell Lysate Preparation
Cells were incubated with ATP, ADP, and UTP (1 to 250 mol/L) for various periods of time (1 to 10 minutes). In some experiments, cells were preincubated with specific inhibitors for 20 minutes. After incubation, cells were placed on ice, washed with ice-cold Tris-buffered saline (20 mmol/L Tris, pH 7.5, 150 mmol/L NaCl), suspended in cell lysis buffer (20 mmol/L Tris, pH 7.5, 100 mmol/L NaCl, 1% [vol/vol] Nonidet P40, 1 mmol/L sodium orthovanadate, 100 mmol/L sodium fluoride, 2 g/mL aprotinin, 1 g/mL leupeptin, 1 mmol/L phenylmethylsulfonyl fluoride, 2.5 mmol/L EDTA, and 1 mmol/L EGTA), scraped, incubated on ice for 20 minutes, and centrifuged at Ϸ14 000g for 5 minutes at 4°C. Supernatants were kept at Ϫ80°C until used for Western blot analysis. Protein concentration was measured by the modified method of Lowry et al, 23 using a detergent-compatible protein assay kit (Bio-Rad, Hercules, Calif).
Western Blot
Cell lysates (30 g protein per well) were analyzed under reducing conditions by SDS-PAGE performed according to Laemmli. 24 Proteins were separated on 4% to 15% polyacrylamide gel and transferred to polyvinylidine difluoride membrane by semidry electroblotting. Membranes were blocked with 5% (wt/ vol) nonfat dry milk and probed overnight at 4°C with specific primary antibodies. Antibodies against human eNOS and phospho-eNOS (Ser-1177), human phospho-AMPK␣ (Thr-172) (Upstate Laboratories, San Diego, Calif), human phospho-Akt (Ser-473; Cell Signaling Technology, Beverly, Mass), human phospho-ERK1/2 (Tyr-204; Santa Cruz Biotechnology, Inc, Santa Cruz, Calif), and GAPDH (Calbiochem/ EMD Biosciences, Inc) were used. Membranes were incubated with secondary donkey anti-rabbit-or goat anti-mouse-horseradish peroxidase-conjugated antibody (Pierce Biotechnology, Rockford, Ill) for 1 hour at room temperature. Protein bands were detected with enhanced chemiluminescence followed by exposure to autoradiography film. Immunoblots were scanned and analyzed with ImageJ 1.33u software (National Institutes of Health, Bethesda, Md).
EC Transfection With siRNA
Cells were transfected with PKC␦_7_HP-validated siRNA or an AllStars negative control siRNA (Qiagen, Valencia, Calif) using Lipofectamine 2000 transfection reagent (Invitrogen, Carlsbad, Calif). Briefly, 50% to 60% confluent ECs grown in 6-well culture plates were transfected in 1 mL Opti MEM I-reduced serum medium with 5 L Lipofectamine 2000 and 100 pmol of the indicated siRNA per well. The cells were incubated at 37°C for 4 to 6 hours, and medium was changed to growth medium. After 48 hours, cells were stimulated with 100 mol/L ATP or UTP for 1 minute, harvested, and analyzed by Western blotting.
Measurement of Intracellular cGMP
ECs were incubated with 100 mol/L ATP or UTP for 20 minutes at 37°C, and intracellular cGMP was measured by a competitive enzyme immunoassay (Cayman Chemical, Ann Arbor, Mich), according to the manufacturer's instructions.
Statistical Analysis
Results are presented as meanϮSE. Data were analyzed by 1-way ANOVA followed by the posthoc Duncan multiple range test when F was significant. Concentration-dependent effects were tested by regression analysis. Differences between groups were rated significant at values of PϽ0.05.
The authors had full access to and take full responsibility for the integrity of the data. All authors have read and agree to the manuscript as written.
Results
Extracellular Nucleotides Induce eNOS Phosphorylation at Ser-1177
ECs were incubated for 1 to 10 minutes with selected nucleotides, ATP, UTP and ADP at concentrations ranging from 1 to 250 mol/L. Results demonstrate that ATP, ADP, and UTP stimulated eNOS phosphorylation in time-and concentration-dependent manners, with maximal phosphorylation occurring within 1 to 2 minutes ( Figure 1A and 1B) . ADP effects were relatively weaker compared with ATP and UTP. In contrast to these nucleotides, similar concentrations of UDP did not induce eNOS phosphorylation (data not shown).
To evaluate a contribution of adenosine originating from extracellular nucleotides hydrolyzed by combined action of ectoenzymes, nucleoside triphosphate diphosphohydrolases, and 5Ј-nucleotidase to eNOS phosphorylation, we used an inhibitor of 5Ј-nucleotidase, AOPCP. Preincubation of ECs with AOPCP (100 mol/L for 20 minutes) did not decrease nucleotide-induced phosphorylation of eNOS ( Figure 2 ).
Increase in [Ca 2؉ ] i Is Required for eNOS Phosphorylation After Treatment With Extracellular Nucleotides
Because eNOS is a calcium/calmodulin-dependent enzyme, it is activated by various agonists that increase [Ca 2ϩ ] i . 25 Because one of the first signals of P2 receptor stimulation is an /mL) , a specific inhibitor of CaMKK, had no effect on nucleotide-induced phosphorylation of eNOS, demonstrating that these kinases are not involved in purinergic activation of eNOS in ECs ( Figures 3B  and 4A, respectively) .
AMPK, Akt, ERK, and p38 MAPK Are Not Implicated in P2 Receptor-Mediated Phosphorylation of eNOS
We have recently shown that extracellular nucleotides activate AMPK in ECs. 21 AMPK has been reported as an upstream kinase in the eNOS pathway. 7 Accordingly, we Akt is another potential kinase involved in eNOS phosphorylation at Ser-1177 in ECs. 6 However, in ECs, nucleotide-induced eNOS phosphorylation usually precedes that of Akt (1 to 2 minutes versus 5 to 10 minutes), which would argue against the implication of Akt in this system. The lack of involvement of Akt was directly validated by our data showing that preincubation of ECs with LY294002 (10 mol/L for 20 minutes), a selective inhibitor of the Akt upstream kinase, PI3K, did not affect phosphorylation of eNOS by ATP or UTP ( Figure 5A ).
Other signaling molecules, including ERK and p38 MAPK that have been implicated in eNOS phosphorylation, also are activation targets of P2 receptor signaling. 22 ECs were preincubated for 20 minutes with the ERK and p38 MAPK inhibitors PD98059 (50 mol/L; inhibits upstream ERK kinase) and SB203580 (10 mol/L), respectively. None of these inhibitors decreased eNOS phosphorylation in response to extracellular nucleotides ( Figure 5B and data not shown).
The PKC␦ Isoform Is Responsible for Nucleotide-Mediated eNOS Phosphorylation and Activation in EC
PKC has been shown to increase eNOS phosphorylation and activity in ECs. 10, 11 P2Y receptors activate phospholipase C, which hydrolyzes phosphatidylinositol bisphosphate into IP3 and diacylglycerol to induce PKC activation. We investigated the role of PKCs in nucleotide-mediated eNOS phosphorylation using pharmacological inhibitors of the various PKC isoforms.
Staurosporine (200 nmol/L; 20-minute preincubation), which originally was recognized as a PKC inhibitor (IC 50 , 5 nmol/L), completely inhibited nucleotide-induced eNOS phosphorylation ( Figure 6A ). However, staurosporine has a much broader specificity and may inhibit PKA (IC 50 , 15 nmol/L), protein kinase G (PKG; IC 50 , 18 nmol/L), and/or CaMK II (IC 50 , 20 nmol/L). We excluded any role for PKA and PKG in nucleotide-induced phosphorylation of eNOS by using their respective inhibitors, 14-22 amide (PKA inhibitor; 10 mol/L) and PKG inhibitor (100 mol/L), which did not attenuate eNOS phosphorylation ( Figure 6B and data not shown). In contrast, we confirmed the participation of PKC in eNOS phosphorylation by using BIM, a non-subtypeselective PKC inhibitor. Preincubation with BIM (5 mol/L for 20 minutes) significantly decreased eNOS phosphorylation in ECs ( Figure 6C ).
Having confirmed PKC involvement in nucleotideinduced phosphorylation of eNOS, we sought to identify the PKC isoform that was responsible. We focused on PKC␣ and PKC␦, which have previously been implicated in eNOS activation in ECs. 10, 11 ECs were preincubated with rottlerin (5 mol/L for 20 minutes), a PKC␦-selective inhibitor, and Gö6976 (1 mol/L for 20 minutes), a PKC␣-specific inhibitor. Rottlerin significantly reduced nucleotidemediated phosphorylation of eNOS, whereas Gö6976 had no effect ( Figure 6D and 6E ). In addition, we verified that extracellular nucleotides induced phosphorylation of PKC␦ at Thr-505, a residue localized in the activation loop of the catalytic domain of this enzyme ( Figure 6E, inset) .
Finally, to confirm participation of PKC␦ in nucleotidemediated eNOS phosphorylation, we used siRNA specific to PKC␦. Transfection of ECs with PKC␦ siRNA significantly reduced extracellular nucleotide-induced eNOS phosphorylation, whereas nontarget, negative control siRNA had no effect ( Figure 6F ).
To examine whether eNOS phosphorylation in response to nucleotides corresponds to eNOS activation and NO generation, we measured NO-induced cGMP production by ELISA 20 minutes after stimulation with nucleotides. ATP/UTP treatment increased intracellular cGMP, reaching levels comparable to those obtained after addition of VEGF (50 ng/mL), a well-known eNOS activator in ECs ( Figure 6G ). cGMP accumulation in control and nucleotide-stimulated ECs was abolished by preincubation with . Activation of PKC␦ by extracellular nucleotides was confirmed by its phosphorylation at Thr-505 (E, inset). Cell lysates were immunoblotted with anti-P-eNOS (Ser-1177), antieNOS, anti-phospho-PKC␦ (P-PKC␦; Thr-505), and anti-PKC␦ antibodies. Results were statistically analyzed and expressed as meanϮSEM of 3 to 7 independent experiments. ϩPϽ0.05 vs ROT. F, Representative Western blots of nontransfected (NT) ECs and ECs transfected for 48 hours with PKC␦-specific or negative control (Ϫ) siRNA and incubated with or without nucleotides (100 mol/L for 1 minute). Cell lysates were immunoblotted with antibodies to P-eNOS (Ser-1177), eNOS, PKC␦, and GAPDH (loading control). Results were statistically analyzed and expressed as meanϮSEM of 4 independent experiments. G, eNOS activity, expressed as cGMP levels, is PKC␦ dependent. ECs were incubated for 20 minutes with 100 mol/L ATP or UTP, with and without L-NAME (100 mol/L) or rottlerin (ROT; 5 mol/L), and cGMP production was measured by the enzyme immunoassay. VEGF (50 ng/mL) was used as a positive control. Results were analyzed statistically and expressed as meanϮSEM of 2 to 4 independent experiments. *PϽ0.05, **PϽ0.01 vs control.
the eNOS inhibitor L-NAME (100 mol/L for 20 minutes), indicating that cGMP is a proper marker of NO production. PKC␦ inhibition by rottlerin significantly attenuated nucleotide-induced cGMP production ( Figure 6G ).
Discussion
The participation of extracellular nucleotides in vessel relaxation has been described and accounted for by NO generation in response to a conformational activation of eNOS by Ca 2ϩ /calmodulin. 26, 27 Besides conformation-based activation, eNOS activity is modulated by its phosphorylation at Ser-1177. Phosphorylation of this residue is recognized as a positive regulator of eNOS activity. 6 The impact of extracellular nucleotides on eNOS phosphorylation has not been clearly defined. In this study, we investigated the mechanism(s) of P2 receptor signaling leading to eNOS phosphorylation and activation in ECs.
We demonstrate that P2 receptor-mediated eNOS phosphorylation at Ser-1177 in ECs is calcium and PKC␦ dependent. We also report that AMPK, Akt, PKA, PKG, CaMK II, CaMKK, p38, and ERK, which are activated by extracellular nucleotides and potential upstream kinases for eNOS, do not participate in this process.
Our results demonstrate that the extracellular nucleotides ATP, UTP, and ADP induce eNOS phosphorylation in timeand concentration-dependent manners (Figure 1) . Furthermore, we established that the prompt nucleotide-mediated eNOS phosphorylation is strictly nucleotide and not adenosine dependent (Figure 2) .
One of the first cellular responses to extracellular nucleotides is an increase in [Ca 2ϩ ] i , which can originate either from the cell milieu (by P2X receptor signaling) or from the intracellular stores (by P2Y receptor signaling).
In previous work, we demonstrated that in ECs Ca 2ϩ is released from intracellular stores (endoplasmic reticulum) after stimulation with extracellular nucleotides. 20 This led us to conclude that in ECs extracellular nucleotides signal mostly via P2Y receptors. Accordingly, extracellular nucleotides are likely to phosphorylate eNOS by engaging P2Y receptors. This conclusion is additionally supported by data showing that nucleotide-induced and NOdependent vasodilation in human vessels is associated with P2Y and not P2X receptors. 27 Here, we examined the effects of ATP (ligand for P2Y2 and P2Y11 receptors), ADP (ligand for P2Y1 and P2Y12 receptors, the latter not expressed in ECs), UTP (ligand for P2Y2 and P2Y4 receptors), and UDP (ligand for P2Y6 receptors) on eNOS phosphorylation. Our results indicate that P2Y1, P2Y2, and possibly P2Y4 receptors are the main receptors involved in purinergic activation of eNOS in ECs. We excluded P2Y6 and P2Y11 receptors because their respective ligands, UDP and BzATP, did not induce eNOS phosphorylation (data not shown).
Our results also demonstrate a crucial role for Ca 2ϩ in nucleotide-induced eNOS phosphorylation. Indeed, eNOS phosphorylation was totally inhibited by chelating intracellular Ca 2ϩ ( Figure 3A) . These results suggest that increased [Ca 2ϩ ] i is necessary for the activation of an upstream kinase involved in eNOS phosphorylation and/or that eNOS cannot be phosphorylated unless calcium-related conformational changes have taken place. Other studies showing that mobilization of [Ca 2ϩ ] i is a crucial step of eNOS activation support our conclusion. 25 Increased [Ca 2ϩ ] i is usually associated with the activation of CaMK II and CaMKK, which, as stated earlier, could act as upstream kinases for eNOS. 5 However, in our experimental system, these enzymes did not participate in the phosphorylation of eNOS ( Figures 3B and 4A) , even though we confirmed in previous work that extracellular nucleotides do activate CaMKK in ECs. 21 There are contradictory results with regard to the role of AMPK in eNOS phosphorylation in ECs. AMPK has been reported as a direct upstream activator of eNOS phosphorylation in ECs stimulated with thrombin and histamine. 7 However, AMPK-independent activation of eNOS also was described in ECs treated with thrombin. 11, 28 Recently, we have shown that extracellular nucleotides activate AMPK in ECs. 21 Therefore, we hypothesized that AMPK could act as an upstream activator of eNOS in our system. Our results disproved this hypothesis. Inhibition of AMPK activity with its pharmacological inhibitor, compound C, attenuated phosphorylation of AMPK but had no effect on nucleotide-induced eNOS phosphorylation ( Figure 4B ). Likewise, inhibition of CaMKK, an upstream AMPK activator, with STO-609 did not affect eNOS phosphorylation ( Figure 4A ). Moreover, dominant-negative AMPK␣2 did not decrease eNOS phosphorylation by extracellular nucleotides (data not shown). Although we have documented in a previous study that extracellular nucleotides do activate AMPK in ECs, 21 in our experimental system, AMPK does not participate in the phosphorylation of eNOS.
Similarly, the participation of Akt in phosphorylation of human eNOS at Ser-1177 was shown in ECs treated with various agonists, including VEGF, thrombin, and histamine. 6 However, here again, nucleotide-induced eNOS phosphorylation was not decreased by pretreatment of ECs with the PI3K inhibitors LY294002 ( Figure 5A ) and wortmannin (data not shown), excluding any participation of the PI3K and Akt kinases in this pathway. We also excluded ERK, p38, PKA, and PKG from any involvement in nucleotide-induced eNOS phosphorylation ( Figure 5B and data not shown).
To scrutinize other potential kinases that are involved in nucleotide-induced eNOS phosphorylation, we investigated participation of the PKC isoforms in purinergic signaling. PKC is a family of serine-threonine-specific kinases, which is divided into 3 groups: the conventional PKCs (␣, ␤I, ␤II, and ␥), the novel PKCs (␦, ⑀, , and ) and the atypical PKCs ( and ). 29 The conventional PKCs depend on calcium and are activated by diacylglycerol; the novel PKCs are calcium independent (but some physiological concentration of Ca 2ϩ is needed) and activated by diacylglycerol; the atypical PKCs are calcium independent and not activated by diacylglycerol. 30 Different PKC isoforms have been shown to exert opposite effects on eNOS activity. Although PKC␤II decreases eNOS activity by phosphorylating Thr-495, 13, 31 PKC␣ and PKC␦ increase eNOS phosphorylation and activity in ECs in response to agonists such as thrombin. 10, 11 In this study, we used an array of various pharmacological inhibitors of PKCs: staurosporine, a selective blocker of PKC; BIM, a PKC inhibitor; rottlerin, a PKC␦ inhibitor; and Gö6976, a PKC␣ inhibitor. Although staurosporine, BIM, and rottlerin significantly inhibited nucleotide-mediated phosphorylation of eNOS, with rottlerin also diminishing cGMP levels, Gö6976 did not affect eNOS phosphorylation (Figure 6 ). In addition, siRNA to PKC␦ significantly attenuated eNOS phosphorylation induced by nucleotides. These combined data indicate that PKC␦ is the main kinase activating eNOS in ECs exposed to extracellular nucleotides.
Accordingly, we propose that on coupling of P2Y 1 and P2Y 2 receptors to phospholipase C via G␣q proteins, diacylglycerol is generated and the level of [Ca 2ϩ ] i is increased, enabling calmodulin and PKC␦ activation and subsequent eNOS phosphorylation, as depicted in Figure 7 . Our demonstration of this pathway clarifies the mechanisms involved in nucleotide-induced eNOS activation through combined Ca 2ϩ -dependent conformational modification, as well as PKC␦-dependent phosphorylation of eNOS.
Conclusions
Our observations strongly suggest that the phosphorylation of eNOS that follows the treatment of ECs with ATP, UTP, and ADP occurs via an increase in the intracellular calcium levels and the activation of PKC␦. We suggest that P2 receptors, by activating eNOS and increasing NO generation, represent novel therapeutic targets for the prevention and/or treatment of endothelial cell dysfunction associated with vascular diseases. 
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